Isis diabetes drug works, but is it competitive?
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals said type 2 diabetes patients treated for 26 weeks with ISIS-PTP1BRx showed statistically significant reductions in hemoglobin A1c (HbA1c) at 36 weeks in a Phase II clinical trial – 10 weeks after treatment ended – but other therapies may provide better efficacy.